Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDA - Pharmaceutical Business Review
- Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDAPharmaceutical Business ReviewWatson Pharmaceuticals has confirmed the filing of ANDA with FDA by Watson Laboratories seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets, 1mg/0
- Watson Confirms Lo Loestrin® Fe Patent Challenge - MarketWatch (press release)
- Watson Confirms Lo Loestrin® Fe Patent ChallengeMarketWatch (press release)
- Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip - The Pharma Letter
- Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic RequipThe Pharma LetterWatson confirmed that it has filed an ANDA with the US Food and Drug Administration seeking approval to market norethindrone acetate/ethinyl estradiol and ethinyl estradiol and ferrous fumarate tablets,1mg/0
- Lilly, Jaguar Land Rover, Viacom: Intellectual Property - BusinessWeek
- Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBusinessWeekLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol
- Lilly, Jaguar Land Rover, Viacom: Intellectual Property - Bloomberg
- Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBloombergLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol
